Title Date
Appendix 4D and Half-Year Financial Report February 18, 2020
Investor Presentation Half Year FY2020 February 18, 2020
Core revenue growth up 19% in Q2 January 28, 2020
SOM - Appendix 4C January 28, 2020
AGM addresses to Shareholders November 21, 2019
Results of Meeting November 21, 2019
SomnoMed Limited signs agreement with App-Nea LLC October 30, 2019
SOM - Appendix 4C October 28, 2019
Strong North American revenue growth in Q1 October 28, 2019
Notice Of Annual General Meeting October 9, 2019
SomnoMed Proxy 2019 October 9, 2019
Appendix 4G September 23, 2019
SOM Annual Report 2019 September 23, 2019
Appointment Sales & Marketing Exec. VP North America September 17, 2019
SelectEquities - Recommendation: Accumulate September 11, 2019
SOM - Appendix 3B September 3, 2019
SOM - Appendix 3Y September 1, 2019
Wilsons - BUY: And suddenly, Germany August 22, 2019
ASX SOM Preliminary Accounts FY19 August 21, 2019
Investor Presentation FY2019 August 21, 2019
Investor Presentation FY2019 August 21, 2019
Morgans - Muddy result, clearer outlook August 21, 2019
Wilsons - BUY: US sales growth equals margin and EPS July 25, 2019
SOM - Appendix 4C July 23, 2019
Wilsons - New BUY: Back to doing what they are world’s best at February 21, 2019
SOM - Appendix 4C January 29, 2019
AGM Results for ASX 2018 November 27, 2018
AGM addresses to Shareholders November 27, 2018
Morgans - Pain for no gain November 27, 2018
Change in Leadership of SomnoMed November 19, 2018
NVA CEO Key Terms November 19, 2018
SOM - Appendix 3B November 19, 2018
SOM - Appendix 4C October 26, 2018
Notice Of Annual General Meeting October 15, 2018
SomnoMed Proxy 2018 October 15, 2018
SOM - Appendix 3B October 3, 2018
SOM Annual Report 2018 September 19, 2018
Wilsons - HOLD: RSS pull-back a necessary mea culpa August 23, 2018
SOM - Appendix 3X – Initial Director’s Interest Notice May 1, 2018
SOM - Appendix 4C April 29, 2018
Form 604 - Notice of change of interests of substantial holder March 22, 2018
SOM - Appendix 3B - Institutional Entitlements March 22, 2018
SOM - Appendix 3Y - Change of Director’s Interest Notice (LA) March 22, 2018
SOM - Appendix 3Y - Change of Director’s Interest Notice (RS) March 22, 2018
Shareholding distribution – Analysis of Holdings as at 22-03-2018 March 22, 2018
Wilsons - HOLD: Recapitalising the US direct-to-patient market channel March 16, 2018
SOM - Appendix 3B - Institutional Entitlements February 27, 2018
SOM - Appendix 3Y - Change of Director’s Interest Notice - PN February 27, 2018
Announcement of Dispatch of Entitlement Offer February 26, 2018
SomnoMed – Successful completion of Institutional Entitlement Offer February 21, 2018
SomnoMed – Retail Entitlement Offer February 20, 2018
SOM - Appendix 3B February 19, 2018
SomnoMed – Announcement of Entitlement Offer February 19, 2018
Trading Halt February 19, 2018
Investor presentation – First half results 2017/18 and Accelerated Entitlement Offer February 18, 2018
SomnoMed – Cleansing Notice February 18, 2018
SomnoMed – Ineligible Shareholders Letter February 18, 2018
ASX Announcement Q2 January 24, 2018
SOM - Appendix 4C January 24, 2018
Form 605 - Notice of ceasing to be a substantial holder December 12, 2017
Morgans - Coming into a seasonally strong period November 21, 2017
AGM Results for ASX 2017 November 20, 2017
Wilsons - BUY: Scrappy 1Q – Europe the powerhouse supporting outlook and RSS investment November 1, 2017
ASX Announcement Q1 October 26, 2017
SOM - Appendix 4C October 26, 2017
Notice of AGM of SomnoMed 2017 October 16, 2017
SOM - Appendix 3B October 5, 2017
SOM - Appendix 3Y October 4, 2017
SOM Annual Report 2017 September 25, 2017
SOM - Appendix 3B September 12, 2017
Form 604 - Notice of change of interests of substantial holder September 8, 2017
Wilsons - BUY: RSS network shaping up nicely August 28, 2017
ASX Preliminary final report August 24, 2017
Investors Presentation FY17 August 24, 2017
Form 604 - Notice of change of interests of substantial holder May 12, 2017
Wilsons - BUY: US channel conflicts abating in Q4 April 27, 2017
Morgans - A transitional year April 26, 2017
Renew Sleep Solutions well ahead of plan April 26, 2017
SOM - Appendix 4C - Quarterly report for entities subject to Listing Rule 4.7B – 26.4.17 April 26, 2017
Wilsons - An eye on RSS channel conflict but the core offering to prevail in US direct market February 24, 2017
Morgans - Sleeping beauty February 23, 2017
SOM - Appendix 4D and Half-Year Financial Report February 23, 2017
Wilsons - RSS taking patients in Oklahoma; good Q2 January 24, 2017
Wilsons - Record Q1, SCA progress and France ratchets up reimbursement for oral appliance therapy October 19, 2016
Notice of AGM of SomnoMed 2016 October 12, 2016
SomnoMed Proxy 2016 October 12, 2016
SOM - Appendix 3B October 7, 2016
SOM Annual Report 2016 September 22, 2016
FDA 510k approval for SomnoDent® Alpha September 21, 2016
SOM - Appendix 3B September 1, 2016
Form 604, Notice of change of interests of substantial holder August 26, 2016
Form 605 Notice of ceasing to be a substantial holder August 26, 2016
SOMApp3YPN August 26, 2016
SOM - Appendix 3B August 25, 2016
Wilsons - Organic goodness August 19, 2016
Investor Presentation FY 2015-2016 August 18, 2016
Morgans - Building for growth August 18, 2016
SOM Preliminary Accounts FY16 August 18, 2016
CEO appointed for new Direct To Patient business entity July 27, 2016
Wilson HTM - Exciting FY17 ahead for core earnings, SCA clinic roll-out and new management July 25, 2016
Q4 ASX June 2016 Quarter Final July 21, 2016
SOM - Appendix 4C – Quarterly report for entities admitted on the basis of commitments July 21, 2016
Derek Smith appointed Global CEO of SomnoMed July 19, 2016
Form 603 - Notice of Initial Substantial Holder July 19, 2016
Form 604 - Notice of change of interests of substantial holder June 6, 2016
SOM - Appendix 3B June 6, 2016
SOM - Appendix 3Y - Change of Director’s Interest Notice - LA June 6, 2016
SOM - Appendix 3Y - Change of Director’s Interest Notice - PN June 6, 2016
SOM - Appendix 3Y - Change of Director’s Interest Notice - RS June 6, 2016
Shareholding Information - Post Entitlement Offer June 6, 2016
Results of Retail Entitlement Offer June 1, 2016
SomnoMed – Results of Institutional Offer June 1, 2016
Wilson HTM – MAS Appeal June 1, 2016
Morgans - Moving down the supply chain May 29, 2016
SOM - Appendix 3B May 13, 2016
Dispatch of letters to shareholders and Retail entitlement offer information booklet May 10, 2016
Announcement of Entitlement Offer May 3, 2016
Cleansing Notice May 3, 2016
Investor Presentation - Sleep Centres America Inc. and Pro rata accelerated entitlement issue May 3, 2016
Letter To Ineligible Shareholders For The Accelerated Non-Renounceable Entitlements Offer May 3, 2016
SOM Chair Letter May 2016 May 3, 2016
SomnoMed - Appendix 3B May 3, 2016
SomnoMed – Letter To Ineligible Shareholders For The Accelerated Non-Renounceable Entitlements Offer May 3, 2016
SOM - Appendix 4C - Quarterly report for entities admitted on the basis of commitments April 20, 2016
Investor Presentation FY 2015-16 Half Year Review February 18, 2016
SOM - Appendix 4D and Half-Year Financial Report February 18, 2016
SelectEquities - Recommendation: Buy January 20, 2016
SOM - Appendix 4C - Quarterly report for entities admitted on the basis of commitments January 19, 2016
Somnomed records 30% growth in direct sales revenues of Somnodent® devices in 1st half of 2015/16 January 19, 2016
Wilson HTM - Sustained European growth underpins a solid Q2 – upgrading FY16 January 19, 2016
Form 603 - Notice of Initial substantial holder January 6, 2016
Frost & Sullivan Recognises Somnomed Limited As Obstructive Sleep Apnea Company Of The Year At The Annual Australian Excellence Awards December 10, 2015
ASX Announcement November 25, 2015
SOM - Appendix 3B - New issue announcement, application for quotation of additional securities and agreement November 25, 2015
SOM - Appendix 4D - Change of Director’s Interest Notice- PN November 25, 2015
SOM - Appendix 3B - New issue announcement, application for quotation of additional securities and agreement November 6, 2015
SomnoMed acquires Strong Dental, Canada November 3, 2015
SOM - Appendix 3B October 30, 2015
SOM - Appendix 3Y - Change of Director’s Interest Notice - LA October 30, 2015
SOM - Appendix 3Y - Change of Director’s Interest Notice - PN October 30, 2015
Notice Of Annual General Meeting 2015 October 23, 2015
SomnoMed Proxy 2015 October 23, 2015
SomnoMed exceeds 250,000 patients October 22, 2015
SOM - Appendix 4G - Key to Disclosures Corporate Governance Council Principles and Recommendations September 28, 2015
SOM Annual Report 2015 September 28, 2015
Form 603 - Notice of initial substantial holder September 7, 2015
ASX Preliminary final report – 30 June 2015 August 20, 2015
Investor Presentation FY 2014-15 August 20, 2015
SOM - Appendix 4C - Quarterly report for entities admitted on the basis of commitments August 13, 2015
SOM - Appendix 3B July 31, 2015
SOM - Appendix 4C July 15, 2015
SomnoMed Announcement – Strong Finish to Financial Year July 15, 2015
Form 605 - Notice of ceasing to be a substantial holder July 2, 2015
Somnomed receives fda 510(k) approval for somnodent® Devices with wearable compliance micro-recording June 22, 2015
Somnomed To Acquire 100% Of SMH Biomaterial AG May 25, 2015
SomnoMed Update May 20, 2015
SOM - Appendix 3B May 7, 2015
Continuous Growth of SomnoMed in Third Quarter April 10, 2015
SOM - Appendix 4С April 10, 2015
Form 605 - Notice of ceasing to be a substantial holder March 11, 2015
Addition of SomnoMed to Australian All Ordinaries Index March 6, 2015
Form 605 - Notice of ceasing to be a substantial holder February 27, 2015
SOM - Appendix 3B February 24, 2015
Investor Presentation FY 2014 – 15 Half Year Review February 18, 2015
SOM - Appendix 4D and Half-Year Financial Report February 18, 2015
SOM - Appendix 4С January 28, 2015
SomnoMed Achieves Growth Targets January 28, 2015
Wilson HTM - 2QFY15 – undeniable strategic value in the sleep market January 28, 2015
SOM - Appendix 3B January 23, 2015
Form 604 - Notice of change of interests of substantial holder December 22, 2014
SOM - Appendix 3B December 22, 2014
SOM - Appendix 3Y - Change of Director’s Interest Notice - RS December 19, 2014
Form 604 - Notice of change of interests of substantial holder December 3, 2014
SOM - Appendix 3B December 3, 2014
SOM - Appendix 3Y - Change of Director’s Interest Notice - LA December 3, 2014
SOM - Appendix 3Y - Change of Director’s Interest Notice - PN December 3, 2014
SOM - Appendix 3Y - Change of Director’s Interest Notice - RS December 3, 2014
ASX Announcement - General Meeting November 26, 2014
Form 604 - Notice of change of interests of substantial holder November 26, 2014
SomnoMed Exceeds 200,000 Patients November 10, 2014
Investor Presentation November 1, 2014
Morgans - Sleeping easy October 31, 2014
Notice Of Annual General Meeting October 23, 2014
Notice of Annual General Meeting October 23, 2014
SOM - Appendix 3B October 21, 2014
Wilson HTM - Strong Q1. Stock fairly valued, move to a HOLD October 17, 2014
New Records in September Confirm Guidance October 16, 2014
SOM - Appendix 4С - Quarterly report for entities admitted on the basis of commitments October 16, 2014
SOM Annual Report 2014 September 29, 2014
US Medicare reimbursement approval granted for SOMNODENT® Herbst Advance September 23, 2014
2014 Share Purchase Plan – Closes Oversubscribed August 22, 2014
SOM - Appendix 3B August 22, 2014
SOM - Appendix 3Y – Change of Director’s Interest Notice - LA August 22, 2014
ASX Preliminary final report – 30 June 2014 August 21, 2014
Investor Presentation FY 2013/14 August 21, 2014
Form 604 - Notice of change of interests of substantial holder August 11, 2014
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) August 8, 2014
SOM - Appendix 3B August 8, 2014
Share Placement Update August 8, 2014
Wilson HTM - Cashing up before cashing in July 28, 2014
SomnoMed USA receives 510K for SomnoDent® Fusion July 24, 2014
Guidance FY 2014/15 July 23, 2014
SOM - Appendix 4C July 23, 2014
SOM - Appendix 3B July 22, 2014
Wilson HTM - Always building something new July 15, 2014
SomnoMed takes over Italian Distribution July 10, 2014
SomnoMed launches two new products in USA June 2, 2014
SomnoMed starts business in Spain and Portugal May 26, 2014
SomnoMed enters UK - Ireland market May 16, 2014
SOM - Appendix 3B May 6, 2014
SomnoMed achieves 28% volume growth in Q3 April 10, 2014
Form 605 - Notice of ceasing to be a substantial holder March 20, 2014
Form 604 - Notice of change of interests of substantial holder March 4, 2014
Wilson HTM - 1HFY14 result March 3, 2014
SelectEquities - Recommendation: Speculative Buy February 28, 2014
SOM Annual Report 2013 September 24, 2013
Wilson HTM - FY14 – further investment in market development September 10, 2013
Somnomed Signs Exclusive Agreement For Compliance Measurement December 11, 2012
SOM - Appendix 3B December 6, 2012
Results of General Meeting November 21, 2012
SOM - Appendix 3B November 21, 2012
SOM - Appendix 3Y – Change of Director’s Interest Notice - PN November 21, 2012
Continuing Global Growth for SomnoMed October 22, 2012
SOM - Appendix 4C October 22, 2012
SomnoMed Acquired 2nd Largest OA Company in France October 9, 2012
SOM Annual Report 2012 September 27, 2012
SomnoMed Appoints New Head For North American Region September 27, 2012
SomnoMed continues to break records in 4th Quarter September 26, 2012
Somnomed Appoints Vp Managed Care For Its North American Operation September 24, 2012
Somnomed Partners With Burkhart Dental Supply September 12, 2012
SOM - Appendix 3B September 11, 2012
ASX Preliminary final report – 30 June 2012 August 31, 2012
SOM - Appendix 4C July 26, 2012
Investor Presentation FY 2011 - 2012 July 1, 2012
SOM Annual Report 2011 September 22, 2011
SOM Annual Report 2010 September 24, 2010

Every State in the United States of America, and most countries throughout the world have their own laws regulating the types of securities and other investment products which maybe offered to their residents, as well as the process for doing so. As a result, investment in some securities is not available to every interested investor. Accordingly, this information is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell Somnomed Limited shares in any jurisdiction where such would be prohibited.

All investments involve different degrees of risk. In making any investment you should be aware of your risk tolerance level and financial situations at all times. Furthermore, you should seek professional investment advice before making any investment decisions. Somnomed Limited and/or its shareholders, directors, officers and/or employees make no investment recommendations in respect to any investment made in Somnomed Limited.